Trends in the management of type 2 diabetes and its prescription drug costs in Greece (1998 & 2006)

Experimental and Clinical Endocrinology and Diabetes

Volumn 117, Issue 9, 2009, Pages 505-510

  Liatis, S ^a   Thomakos, P ^a   Papaoikonomou, S ^a   Papazafeiropoulou, A ^b   Giannakopoulos, N ^c   Karagiaouri, E ^c   Sotiropoulos, A ^b   Bousboulas, S ^b   Melidonis, A ^c   Pappas, S ^b   Katsilambros, N ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b GENERAL HOSPITAL OF NIKEA   (Greece)

^c TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

Author keywords

Cardiovascular risk factors; Economics; Glycaemic control; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OMEGA 3 FATTY ACID; ORAL ANTIDIABETIC AGENT; RENIN INHIBITOR; SULFONYLUREA; TICLOPIDINE;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES CONTROL; DRUG COST; FEMALE; GREECE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR;

AGED; DIABETES MELLITUS, TYPE 2; DIET THERAPY; DISEASE MANAGEMENT; DRUG COSTS; DRUG UTILIZATION; FEMALE; GREECE; HEALTH CARE COSTS; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; PRESCRIPTION DRUGS; PRESCRIPTIONS; RISK FACTORS;

EID: 70449445714     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0029-1225338     Document Type: Article

References (35)

1. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007 13 (Suppl 1) 1-68
2. Alexander GC, Sehgal NL, Moloney RM, et al. National trends in treatment of type 2 diabetes mellitus, 19942007. Arch Intern Med 2008 168 2088-2094
3. Hogan P, Dall T, Nikolov P. American Diabetes Association. Economic Costs of Diabetes in the U.S. Diabetes Care 2003 26 917-932
4. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2000 23 (Suppl 1) S32-S42
5. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008 31 (Suppl 1) S12-S54
6. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997 14 (Suppl 5) S1-S85
7. Arnold-Wörner N, Holle R, Rathmann W, et al. The importance of specialist treatment, treatment satisfaction and diabetes education for the compliance of subjects with type 2 diabetes results from a population-based survey. Exp Clin Endocrinol Diabetes 2008 116 123-128
8. Bagust A, Hopkinson PK, et al. An economic model of the long-term health care burden of Type II diabetes. Diabetologia 2001 44 2140-2155
9. Colhoun HM, Betteridge DJ, Durrington PN, et al CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 364 685-696
10. Collins R, Armitage J, Parish S, et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 361 2005-2016
11. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003 289 2254-2264
12. Ford ES, Li C, Little RR, et al. Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 2008 31 102-104
13. Gaede P, Valentine WJ, Palmer AJ, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008 31 1510-1515
14. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 348 383-393 (Pubitemid 36159355)
15. Goudswaard AN, Furlong NJ, Rutten GE, et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2004 18 (4) CD003418
16. Greving JP, Denig P, de Zeeuw D, et al. Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 19982004: a longitudinal observational study. Cardiovasc Diabetol 2007 20 6-25
17. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 351 1755-1756
18. Huppertz E, Pieper L, Klotsche J, et al. Diabetes Mellitus in German Primary Care: quality of glycaemic control and subpopulations not well controlled results of the DETECT Study. Exp Clin Endocrinol Diabetes 2009 117 6-14
19. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006 23 579-593 in 2007. Diabetes Care 2008; 31:591615
20. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care 2000 23 390-404
21. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005 65 385-411
22. Kusnik-Joinville O, Weill A, Salanave B, et al. Prevalence and treatment of diabetes in France: trends between 2000 and 2005. Diabetes Metab 2008 34 266-272
23. Lebovitz HE. Oral antidiabetic agents. Med Clin North Am 2004 88 847-863 ixx.
24. Liatis S. Treatment of diabetes with insulin. In Katsilambros N, Diabetes in Clinical Practice The Atrium, Southern Gate, Chichester: John Wiley and Sons, Ltd. 2006 371-408
25. Martin S, Schramm W, Schneider B, et al. Epidemiology of complications and total treatment costs from diagnosis of type 2 diabetes in Germany (ROSSO 4). Exp Clin Endocrinol Diabetes 2007 115 495-501
26. Rathmann W, Haastert B, Icks A, et al. Trends in outpatient prescription drug costs in diabetic patients in Germany, 19942004. Diabetes Care 2007 30 848-853
27. Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005 20 (3) CD002966
28. Schunk M, Schweikert B, Gapp O, et al. Time Trends in Type 2 Diabetes Patients Disease Management and Outcomes: Evidence from Two KORA Surveys in Germany. Exp Clin Endocrinol Diabetes 2008 Aug 25 Epub ahead of print
29. Schwarz PE, Lindström J, Kissimova-Scarbeck K, et al. DE-PLAN project. The European perspective of type 2 diabetes prevention: Diabetes in Europe Prevention using Lifestyle, physical Activity and Nutritional intervention (DE-PLAN) project. Exp Clin Endocrinol Diabetes 2008 116 167-172
30. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 837-853
31. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1999 317 703-713
32. UKPDS Group. Cost-effectiveness analysis of improved blood pressure control in hypertensive patients with Type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. Br Med J 1998 317 720-726
33. UKPDS Group. Cost-effectiveness of an intensive blood glucose control policy in patients with Type 2 diabetes: economic analysis alongside a randomised controlled trial. UKPDS 41. UK Prospective Diabetes Study Group. Br Med J 2000 320 1373-1378
34. von Ferber L, Köster I, Hauner H. Medical costs of diabetic complications total costs and excess costs by age and type of treatment results of the German CoDiM Study. Exp Clin Endocrinol Diabetes 2007 115 97-104
35. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001 24 758-767